subsidiaries by having the main substance is as follows. (Unit: Thousand Baht) Revenues Gross Profit Selling Admin Net profit 2017 837,308 293,207 80,159 93,260 -236,013 2018 929,354 325,527 88,001 79,800
, 2018 of the Company and its subsidiaries by having the main substance is as follows. (Unit: Thousand Baht) In overall, the Company and its subsidiaries had the net profit in Q3/2018 at 32.7 MB increased
results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
proven resilient in the past and we expect this to continue into the rest of 2019. The main lime consuming sectors of the industry were not immune to the disruption: the sugar cane harvest was down after a
%, because the price of natural rubber, which is the main raw material for production, decreased. • Selling expenses decreased 2.46 million baht or 6.04 % due to higher operating efficiency and other expenses
previous year which a net loss of Baht 6.39 million, the loss increase Baht 3.6 million or increase by 56.34% , the main reasons are as follow 1. Revenue from sale , Other income The company had revenue from
to the same period of previous year which a net loss of Baht 24.73 million, the loss decrease Baht 19.3 million or decrease by 78.03% , the main reasons are as follow 1. Revenue from sale , Other
a net loss of 8.46 million baht, the increased loss of 7.29 million baht, the main reasons are as follow; 1. Revenue from sale , Other income The company had sale revenue at the end of Quarter 2 ended
previous year which a net loss of Baht 9.99 million, the loss decrease Baht 1.54 million or decrease by 15.36% , the main reasons are as follow 1. Revenue from sale , Other income The company had revenue
of 14.73 million baht, the decreased loss of 8.53 million or decreased loss percentages of 57.91% , the main reasons are as follow; 1. Revenue from sale , Other income The company had sale revenue at